Recombinant Cynomolgus PTGFRN(Met1-Lys830) fused with His tag at C-terminal was expressed in HEK293.
EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.
Predicted N Terminal:
Lyophilized from sterile PBS, pH 7.4.
The recombinant cynomolgus PTGFRN comprises 816 amino acids and has a calculated molecular mass of 91.5 KDa. The apparent molecular mass of it is approximately 96-106 KDa in SDS-PAGE under reducing conditions.
< 1.0 EU per μg of the protein as determined by the LAL method
> 95 % as determined by SDS-PAGE
Samples are stable for up to twelve months from date of receipt at -70 centigrade
Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.